generic drugs /biosimilars Archives - ACHP

Ending the Allure of Drug Advertising

ACHP calls on Congress to curb direct-to-consumer (DTC) drug ad dominance. Patients should be able to access affordable, necessary medications, rather than being swayed by misleading marketing tactics.

ACHP Letter to Acting FDA Commissioner on the Accelerated Approval of Drugs and Biologics

ACHP sent a letter to FDA’s Acting Commissioner, Sara Brenner, with comments on the Expedited Program for Serious Conditions.

How a National Risk Pool Can Transform Gene & Cell Therapies

For patients suffering from rare, debilitating diseases, cell and gene therapies offer a source of hope. These innovative treatments are tailored to individual patients’ DNA, which makes them uniquely effective. But there is one major problem – the staggeringly high price tag.

PBM Transparency, Enhanced Premium Tax Credits in ACHP’s Year-End Priorities for Congress

ACHP recently sent a letter to Congress expressing the health care priorities we hope to see before the legislative session concludes.

ACHP Letter on Patent Reform

ACHP submitted a comment letter to the United States Patent and Trademark Office on double patenting, or “patent thickets.”